SHIM
NTLA icon

Stone House Investment Management’s Intellia Therapeutics NTLA Stock Holding History

Stone House Investment Management’s Portfolio NTLA Stock Details NTLA Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2024
Q3 		– Sell
-52
Closed -$1.16K – 412
2024
Q2 		$1.16K Sell
52
-22
-30% -$524 ﹤0.01% 353
2024
Q1 		$2.04K Sell
74
-78
-51% -$2.17K ﹤0.01% 347
2023
Q4 		$4.63K Buy
152
+100
+192% +$2.87K ﹤0.01% 221
2023
Q3 		$1.64K Hold
52
– – ﹤0.01% 273
2023
Q2 		$2.12K Hold
52
– – ﹤0.01% 264
2023
Q1 		$1.94K Buy
+52
New +$2.04K ﹤0.01% 251

Other funds holding NTLA

AIM
ARK Investment Management St. Petersburg, Florida $12.9B AUM 64.92% 1-Year Est. Return
BlackRock
BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return
DTC
Deep Track Capital Greenwich, Connecticut $6.12B AUM 144% 1-Year Est. Return
Sumitomo Mitsui Trust Group
Sumitomo Mitsui Trust Group Minato-Ku, Tokyo, Japan $175B AUM 40.63% 1-Year Est. Return
NAMA
Nikko Asset Management Americas New York $7.07B AUM 50.91% 1-Year Est. Return
Federated Hermes
Federated Hermes Pittsburgh, Pennsylvania $61.5B AUM 30.7% 1-Year Est. Return
Morgan Stanley
Morgan Stanley New York $1.66T AUM 25.57% 1-Year Est. Return
Geode Capital Management
Geode Capital Management Boston, Massachusetts $1.61T AUM 30.72% 1-Year Est. Return

Stone House Investment Management's NTLA Position: Q3 2024 in Review

Stone House Investment Management sold out of Intellia Therapeutics (NTLA) in Q3 2024, closing a stake of 52 shares — an estimated $1.16K sold.

Stone House Investment Management first reported a position in NTLA in Q1 2023 and held it in 6 quarters. The position peaked at $4.63K in Q4 2023. 284 funds tracked by Wall St. Rank hold NTLA as of Q3 2024.

  • Stone House Investment Management reported no remaining Intellia Therapeutics position as of Q3 2024 after selling out during the quarter.
  • Stone House Investment Management sold 52 Intellia Therapeutics shares in Q3 2024, an estimated $1.16K.
  • Stone House Investment Management first reported a position in Intellia Therapeutics in Q1 2023 and held it in 6 quarters.
  • Stone House Investment Management's Intellia Therapeutics position peaked at $4.63K in Q4 2023.
  • 284 funds tracked by Wall St. Rank held Intellia Therapeutics as of Q3 2024.

Based on Stone House Investment Management's 13F filing for Q3 2024, filed 13 Nov 2024.